|
This product requires a valid prescription
|
Innohep (Tinzaparin Sodium) is indicated for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium.
The safety and effectiveness of Innohep (Tinzaparin Sodium) were established in hospitalized patients. Innohep (Tinzaparin Sodium) is a low molecular weight heparin. Heparin and tinzaparin (anticoagulants) work by interfering with the body's natural blood clotting mechanism. This mechanism involves a series of complex pathways. Heparin and tinzaparin inactivate a compound in this pathway called thrombin, which plays an important role in blood clot formation. Therefore, heparin and tinzaparin prevent the formation of blood clots in the body. Innohep (Tinzaparin Sodium) has many advantages over normal heparin. These include a more effective anticoagulant effect and reduced risk of bleeding. Innohep (Tinzaparin Sodium) is given by injection under the skin, and is used for the treatment of blood clots in conditions such as deep vein thrombosis and pulmonary embolism and the prevention of blood clots following surgery. Tinzaparin is also used to prevent clots forming in blood during kidney dialysis. Innohep (Tinzaparin Sodium) side effects: The following are some of the side effects that are known to be associated with Innohep (Tinzaparin Sodium). However, not all people using Innohep will experience these side effects: Allergy to active ingredients (hypersensitivity) Skin rashes Alteration in results of liver function tests Bleeding (haemorrhage) High blood potassium level (hyperkalaemia) Bruising or pain at injection site Decrease in the number of platelets in the blood (thrombocytopenia) Decreased production of aldosterone, a steroid hormone which regulates salt and water balance (hypoaldosteronism) |
 |
  |
|